ArticleNeurology2013
Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI.
Article in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03022357 (Nigrosomal Iron Imaging in Parkinson's Disease), which is not on this map. Cited by 143 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nigrosomal Iron Imaging in Parkinson's Disease
Who cites it
143 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Is the Swallow Tail Sign a Useful Imaging Biomarker in Clinical Neurology? A Systematic Review.Movement disorders clinical practice · 2025Pooled it
- Loss of the "swallow tail sign" on susceptibility-weighted imaging in the diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis.Journal of neurology · 2024Pooled it
- Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in parkinsonism: an updated meta-analysis.European radiology · 2021Pooled it
- MatchingFrontiers in neuroanatomy · 2019Pooled it
- Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders.Current neurology and neuroscience reports · 2018Pooled it
- Substantia nigra fractional anisotropy is not a diagnostic biomarker of Parkinson's disease: A diagnostic performance study and meta-analysis.European radiology · 2017Pooled it
- Trial
- Volumetric and Intrastructural Characterization of the Substantia Nigra Using Optimized Synthetic MR Images Derived From Quantitative T1 Maps at 3 T.NMR in biomedicine · 2026Article
- The swallow tail sign: mechanisms, neuroimaging advances and future perspectives.Insights into imaging · 2026Article
- Calbindin stratifies midbrain dopaminergic neurons governing distinct aspects of locomotion.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A neuroimaging atlas of the nigrosomes in the substantia nigra based on 3D histology.Scientific data · 2026Article
- Quantitative Assessment of Visible Nigrosome-1 in Patients with Parkinson's Disease.Movement disorders clinical practice · 2026Article
- 7 Tesla MRI with Quantitative Susceptibility Mapping: qualitative grading and quantitative focal measurements of the substantia nigra as a potential biomarker for Parkinson's disease.Neuroradiology · 2026Article
- Neuroimaging of the monoaminergic system in Parkinson's disease: A narrative review.Neuroimage. Reports · 2026Review
- Postpartum psychosis is associated with elevated neuromelanin-MRI signal in the midbrain.Molecular psychiatry · 2026Article
- Superior dorsal nigral hyperintensity depiction at 7 T MRI using CLEAR-DESS improves diagnosis performance of Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Towards biomarker-based diagnosis of Parkinson disease.Nature reviews. Neurology · 2026Review
- Sex-dependent dopaminergic vulnerability may contribute to sex differences in Parkinson's disease risk.Brain communications · 2026Article
- Integrated evaluation of Nigrosome 1 sign, neuromelanin-sensitive MR and iron deposition.Japanese journal of radiology · 2026Article
- Isolated auditory hallucinations as the initial neuropsychiatric manifestation of dementia with Lewy bodies: diagnostic pathway and individualized therapy (a case report).Frontiers in psychiatry · 2026Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byAuthor response.2014
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study assessed whether high-resolution 7 T MRI allowed direct in vivo visualization of nigrosomes, substructures of the substantia nigra pars compacta (SNpc) undergoing the greatest and earliest dopaminergic cell loss in Parkinson disease (PD), and whether any disease-specific changes could be detected in patients with PD.
methodsPostmortem (PM) midbrains, 2 from healthy controls (HCs) and 1 from a patient with PD, were scanned with high-resolution T2*-weighted MRI scans, sectioned, and stained for iron and neuromelanin (Perl), TH, and calbindin. To confirm the identification of nigrosomes in vivo on 7 T T2*-weighted scans, we assessed colocalization with neuromelanin-sensitive T1-weighted scans. We then assessed the ability to depict PD pathology on in vivo T2*-weighted scans by comparing data from 10 patients with PD and 8 age- and sex-matched HCs.
resultsA hyperintense, ovoid area within the dorsolateral border of the otherwise hypointense SNpc was identified in the HC brains on in vivo and PM T2*-weighted MRI. Location, size, shape, and staining characteristics conform to nigrosome 1. Blinded assessment by 2 neuroradiologists showed consistent bilateral absence of this nigrosome feature in all 10 patients with PD, and bilateral presence in 7/8 HC.
conclusionsIn vivo and PM MRI with histologic correlation demonstrates that high-resolution 7 T MRI can directly visualize nigrosome 1. The absence of nigrosome 1 in the SNpc on MRI scans might prove useful in developing a neuroimaging diagnostic test for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.